- Home
- CPZ vs STRO Comparison
CPZ vs STRO Comparison
Compare CPZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- STRO
- Stock Information
- Founded
- CPZ 2019
- STRO 2003
- Country
- CPZ United States
- STRO United States
- Employees
- CPZ N/A
- STRO N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPZ Finance
- STRO Health Care
- Exchange
- CPZ Nasdaq
- STRO Nasdaq
- Market Cap
- CPZ 305.7M
- STRO 172.8M
- IPO Year
- CPZ N/A
- STRO 2018
- Fundamental
- Price
- CPZ $15.35
- STRO $1.87
- Analyst Decision
- CPZ
- STRO Strong Buy
- Analyst Count
- CPZ 0
- STRO 7
- Target Price
- CPZ N/A
- STRO $12.14
- AVG Volume (30 Days)
- CPZ 63.0K
- STRO 1.4M
- Earning Date
- CPZ 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- CPZ 11.07%
- STRO N/A
- EPS Growth
- CPZ N/A
- STRO N/A
- EPS
- CPZ N/A
- STRO N/A
- Revenue
- CPZ N/A
- STRO $160,955,000.00
- Revenue This Year
- CPZ N/A
- STRO N/A
- Revenue Next Year
- CPZ N/A
- STRO N/A
- P/E Ratio
- CPZ N/A
- STRO N/A
- Revenue Growth
- CPZ N/A
- STRO 230.90
- 52 Week Low
- CPZ $13.17
- STRO $1.70
- 52 Week High
- CPZ $16.11
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- CPZ 49.11
- STRO 28.52
- Support Level
- CPZ $14.86
- STRO $1.70
- Resistance Level
- CPZ $15.42
- STRO $1.93
- Average True Range (ATR)
- CPZ 0.24
- STRO 0.20
- MACD
- CPZ -0.00
- STRO -0.01
- Stochastic Oscillator
- CPZ 55.06
- STRO 12.60
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.